venlafaxine hydrochloride has been researched along with Ataxia in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Necpál, J; Skorvanek, M | 1 |
| Bourgeois, JA; Cogswell, JB; Hagerman, RJ; Hall, DA; Nguyen, DV; Olichney, J; Ortigas, MC; Schneider, A | 1 |
| Bourgeois, JA; Brunberg, JA; Farzin, F; Hagerman, P; Hagerman, R; Hessl, D; Tassone, F; Zhang, L | 1 |
| Brocco, M; Dekeyne, A; Girardon, S; Millan, MJ; Veiga, S | 1 |
4 other study(ies) available for venlafaxine hydrochloride and Ataxia
| Article | Year |
|---|---|
Opsoclonus-myoclonus ataxia syndrome secondary to venlafaxine intoxication.
Topics: Adult; Antidepressive Agents, Second-Generation; Ataxia; Depression; Female; Humans; Opsoclonus-Myoclonus Syndrome; Stress Disorders, Post-Traumatic; Venlafaxine Hydrochloride | 2017 |
Improving fragile X-associated tremor/ataxia syndrome symptoms with memantine and venlafaxine.
Topics: Aged; Ataxia; Cyclohexanols; Drug Therapy, Combination; Female; Follow-Up Studies; Fragile X Mental Retardation Protein; Fragile X Syndrome; Humans; Memantine; Tremor; Venlafaxine Hydrochloride | 2010 |
Dementia with mood symptoms in a fragile X premutation carrier with the fragile X-associated tremor/ataxia syndrome: clinical intervention with donepezil and venlafaxine.
Topics: Aged; Antidepressive Agents, Second-Generation; Ataxia; Atrophy; Brain; Cyclohexanols; Dementia; Dominance, Cerebral; Donepezil; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fragile X Mental Retardation Protein; Fragile X Syndrome; Genetic Carrier Screening; Humans; Image Processing, Computer-Assisted; Indans; Magnetic Resonance Imaging; Male; Mental Status Schedule; Mood Disorders; Neurologic Examination; Neuropsychological Tests; Nootropic Agents; Piperidines; Tremor; Trinucleotide Repeats; Venlafaxine Hydrochloride | 2006 |
Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake. A pharmacological characterization of diverse classes of antidepressant agents.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Ataxia; Citalopram; Cyclohexanols; Dose-Response Relationship, Drug; Environment; Hyperkinesis; Mice; Motor Activity; Receptors, Adrenergic, alpha-2; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2002 |